Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Mix

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
The Lancet. Oncology|March 16, 2020
Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trialUrsula Nestle, Tanja Schimek-Jasch, Stephanie Kremp, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 26, 2021
Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trialEleni Gkika, Tanja Schimek-Jasch, Stephanie Kremp, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 31, 2020
Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural NetworkDejan Kostyszyn, Tobias Fechter, Nico Bartl, et al.
Cancers|November 18, 2020
Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer-A Secondary Analysis of the PET Plan TrialEleni Gkika, Stefan Lenz, Tanja Schimek-Jasch, et al.
The Lancet. Oncology|December 22, 2025
O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trialAnca-Ligia Grosu, Wolfgang A Weber, Erika Graf, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 19, 2022
The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysisSimon K B Spohn, Andrea Farolfi, Sarah Schandeler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 17, 2023
Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapySimon K B Spohn, Nina-Sophie Schmidt-Hegemann, Juri Ruf, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 14, 2021
Value of PET imaging for radiation therapyConstantin Lapa, Ursula Nestle, Nathalie L Albert, et al.
Nuklearmedizin. Nuclear Medicine|July 14, 2021
Value of PET imaging for radiation therapyConstantin Lapa, Ursula Nestle, Nathalie L Albert, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|October 7, 2021
Correction to: Value of PET imaging for radiation therapyConstantin Lapa, Ursula Nestle, Nathalie L Albert, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
The Lancet. Oncology|March 16, 2020
Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trialUrsula Nestle, Tanja Schimek-Jasch, Stephanie Kremp, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 26, 2021
Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trialEleni Gkika, Tanja Schimek-Jasch, Stephanie Kremp, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 31, 2020
Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural NetworkDejan Kostyszyn, Tobias Fechter, Nico Bartl, et al.
Cancers|November 18, 2020
Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer-A Secondary Analysis of the PET Plan TrialEleni Gkika, Stefan Lenz, Tanja Schimek-Jasch, et al.
The Lancet. Oncology|December 22, 2025
O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trialAnca-Ligia Grosu, Wolfgang A Weber, Erika Graf, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 19, 2022
The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysisSimon K B Spohn, Andrea Farolfi, Sarah Schandeler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 17, 2023
Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapySimon K B Spohn, Nina-Sophie Schmidt-Hegemann, Juri Ruf, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 14, 2021
Value of PET imaging for radiation therapyConstantin Lapa, Ursula Nestle, Nathalie L Albert, et al.
Nuklearmedizin. Nuclear Medicine|July 14, 2021
Value of PET imaging for radiation therapyConstantin Lapa, Ursula Nestle, Nathalie L Albert, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|October 7, 2021
Correction to: Value of PET imaging for radiation therapyConstantin Lapa, Ursula Nestle, Nathalie L Albert, et al.
Pageof 12